The FDA last week granted a sweeping label expansion to Eli Lilly’s Retevmo, approving the drug for any cancers with locally advanced or metastatic solid tumors with rearranged during transfection (RET) gene fusion. The RET inhibitor will be available to adult patients whose tumors have not responded to prior treatments or have no alternative treatment options. Retevmo was first approved in 2020 for RET-fusion non-small cell lung cancer (NSCLC) and thyroid cancers. For these indications, the drug currently holds covered or better status for 93% of all insured lives under the pharmacy benefit. Just 6% of insured lives have preferred access to Retevmo, however, growing to 18% with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 9/26/22